TabsDetailsBasic DetailsDate Posted: Friday, January 24, 2020Status: CompleteMedical Product: atorvastatin, rosuvastatin, ticagrelorDescription: In this report we evaluated concurrent use of ticagrelor (all strength, 60mg, and 90mg) with atorvastatin or rosuvastatin in the Sentinel Distributed Database (SDD).The study period included data from January 1, 2012 to June 30, 2018. We distributed this request to 17 Data Partners on January 8, 2019. Read More Deliverables (1)Sentinel Modular Program Report: Concurrent Use of Ticagrelor with Atorvastatin or RosuvastatinAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2012 - June 30, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: 2019 AHA Scientific Sessions Poster: Myopathy and Rhabdomyolysis with Concomitant Use of Ticagrelor and High-Intensity Statins in the Elderly
